Trial · NCT03331835
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Having Least 75% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 75 Response) From Baseline at Week 24 | Brodalumab | 85 | Participants | ||
| Having Least 75% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 75 Response) From Baseline at Week 24 | Fumaric Acid Esters | 40 | Participants | ||
| Static Physician's Global Assessment (sPGA) Scale Score of 0 or 1 at Week 24 | Brodalumab | 68 | Participants | ||
| Static Physician's Global Assessment (sPGA) Scale Score of 0 or 1 at Week 24 | Fumaric Acid Esters | 21 | Participants | ||
| Having Least 90% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 90 Response) From Baseline at Week 24 | Brodalumab | 69 | Participants | ||
| Having Least 90% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 90 Response) From Baseline at Week 24 | Fumaric Acid Esters | 23 | Participants | ||
| Having 100% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 100 Response) From Baseline at Week 24 | Brodalumab | 42 | Participants | ||
| Having 100% Lower Psoriasis Area and Severity Index (PASI) Score Relative to Baseline (PASI 100 Response) From Baseline at Week 24 | Fumaric Acid Esters | 9 | Participants | ||
| Change From Baseline at Week 24 in PASI Score | Brodalumab | -15.69 | Standard Error 0.59 | score on a scale | |
| Change From Baseline at Week 24 in PASI Score | Fumaric Acid Esters | -12.62 | Standard Error 0.67 | score on a scale | |
| Percent Change From Baseline in PASI Score at Week 24 | Brodalumab | -90.03 | Standard Error 2.25 | percent change in PASI | |
| Percent Change From Baseline in PASI Score at Week 24 | Fumaric Acid Esters | -73.67 | Standard Error 2.63 | percent change in PASI | |
| Change From Baseline at Week 24 in Affected Body Surface Area (BSA) | Brodalumab | -20.82 | Standard Error 1.48 | percent change | |
| Change From Baseline at Week 24 in Affected Body Surface Area (BSA) | Fumaric Acid Esters | -11.91 | Standard Error 1.48 | percent change | |
| Psoriasis Symptom Inventory (PSI) Responder at Week 24 (Total Score ≤ 8, With no Item Scores > 1) | Brodalumab | 15 | Participants | ||
| Psoriasis Symptom Inventory (PSI) Responder at Week 24 (Total Score ≤ 8, With no Item Scores > 1) | Fumaric Acid Esters | 13 | Participants | ||
| PSI Total Score of 0 at Week 24 | Brodalumab | 5 | Participants | ||
| PSI Total Score of 0 at Week 24 | Fumaric Acid Esters | 3 | Participants | ||
| Number of Symptom-free Days From Randomisation to Week 24 | Brodalumab | 0.44 | Standard Deviation 0.8 | days | |
| Number of Symptom-free Days From Randomisation to Week 24 | Fumaric Acid Esters | 0.42 | Standard Deviation 1.3 | days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03331835/results